Aliases & Classifications for Hypogonadism, Male

MalaCards integrated aliases for Hypogonadism, Male:

Name: Hypogonadism, Male 58
Male Hypogonadism 38 30
Testicular Hypogonadism 74
Hypogonadism Male 56

Characteristics:

OMIM:

58
Inheritance:
autosomal recessive


HPO:

33
hypogonadism, male:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 58 241100
KEGG 38 H02027
MedGen 43 C0151721
UMLS 74 C0151721

Summaries for Hypogonadism, Male

OMIM : 58 Familial male hypogonadism is a highly heterogeneous category from which some disorders such as Reifenstein syndrome (312300), Kallmann syndrome (see 308700), isolated gonadotropin deficiency, and some other entities can be separated. The presence of an autosomal recessive form is suggested by the occurrence of parental consanguinity (Nowakowski and Lenz, 1961). (241100)

MalaCards based summary : Hypogonadism, Male, also known as male hypogonadism, is related to ichthyosis and male hypogonadism and hypogonadism, male, with mental retardation and skeletal anomalies. An important gene associated with Hypogonadism, Male is LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor), and among its related pathways/superpathways is Prolactin Signaling Pathway. The drugs Testosterone and Testosterone enanthate have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and bone marrow, and related phenotypes are testicular atrophy and male hypogonadism

Related Diseases for Hypogonadism, Male

Diseases related to Hypogonadism, Male via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 ichthyosis and male hypogonadism 12.3
2 hypogonadism, male, with mental retardation and skeletal anomalies 12.2
3 leydig cell hypoplasia, type i 11.3
4 alstrom syndrome 11.0
5 myotonic dystrophy 2 11.0
6 wolfram syndrome 11.0
7 hypogonadism 10.5
8 hypogonadotropism 10.4
9 infertility 10.1
10 hypogonadotropic hypogonadism 10.1
11 osteoporosis 10.0
12 estrogen excess 10.0
13 amenorrhea 9.9 LEP LHCGR
14 body mass index quantitative trait locus 1 9.9
15 bone fracture 9.9
16 gynecomastia 9.9
17 ichthyosis 9.9
18 47,xyy 9.9
19 47, xxy 9.9
20 coronary artery aneurysm 9.9 KLK3 LEP
21 autoimmune disease 9.8
22 breast cancer 9.8
23 galactorrhea 9.8
24 aging 9.8
25 autoimmune disease 1 9.8
26 myocardial infarction 9.8
27 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
28 bone mineral density quantitative trait locus 8 9.8
29 bone mineral density quantitative trait locus 15 9.8
30 ichthyosis lamellar 1 9.8
31 thalassemia 9.8
32 sexual disorder 9.8
33 cogan syndrome 9.8
34 infant gynecomastia 9.8
35 hypothyroidism 9.8
36 impotence 9.8
37 fatty liver disease 9.8
38 dwarfism 9.8
39 rud syndrome 9.8
40 distal trisomy 3p 9.8
41 systemic lupus erythematosus 9.8
42 prostate cancer 9.8
43 prostate cancer, hereditary, 8 9.8
44 prostate cancer, hereditary, 6 9.8
45 bone resorption disease 9.8
46 pre-eclampsia 9.8
47 eclampsia 9.8
48 pituitary gland disease 9.8
49 lupus erythematosus 9.8
50 myotonic dystrophy 9.8

Graphical network of the top 20 diseases related to Hypogonadism, Male:



Diseases related to Hypogonadism, Male

Symptoms & Phenotypes for Hypogonadism, Male

Human phenotypes related to Hypogonadism, Male:

33
# Description HPO Frequency HPO Source Accession
1 testicular atrophy 33 HP:0000029
2 male hypogonadism 33 HP:0000026
3 hypospadias 33 HP:0000047
4 gynecomastia 33 HP:0000771
5 micropenis 33 HP:0000054

Symptoms via clinical synopsis from OMIM:

58
G U:
male hypogonadism
hypospadias
small penis
normal-sized testes

Misc:
markedly diminished secondary sexual characteristics

Thorax:
gynecomastia

Clinical features from OMIM:

241100

GenomeRNAi Phenotypes related to Hypogonadism, Male according to GeneCards Suite gene sharing:

27 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.4 BGLAP LEP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.4 BGLAP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.4 BGLAP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.4 LEP
5 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.4 BGLAP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.4 BGLAP
7 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.4 BGLAP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.4 BGLAP
9 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.4 BGLAP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.4 BGLAP
11 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.4 LEP

Drugs & Therapeutics for Hypogonadism, Male

Drugs for Hypogonadism, Male (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0, 481-30-1 6013 10204
2
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
3
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
4
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Calcium Approved, Nutraceutical Phase 4,Phase 2 7440-70-2 271
8
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
11 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Calcium, Dietary Phase 4,Phase 2
19 Insulin, Globin Zinc Phase 4,Phase 3,Not Applicable
20 insulin Phase 4,Phase 3,Not Applicable
21 Calciferol Phase 4
22 Bone Density Conservation Agents Phase 4
23 Ergocalciferols Phase 4
24 Vitamin D2 Phase 4
25 Nutrients Phase 4
26 Trace Elements Phase 4
27 Vitamins Phase 4
28 Micronutrients Phase 4
29 Estradiol 17 beta-cypionate Phase 4
30 Estradiol 3-benzoate Phase 4
31 Follicle Stimulating Hormone Phase 4
32 Pharmaceutical Solutions Phase 4
33
Coal tar Approved Phase 3 8007-45-2
34
Metformin Approved Phase 3 657-24-9 14219 4091
35 Hypoglycemic Agents Phase 3,Not Applicable
36
Sodium Citrate Approved, Investigational Phase 2 68-04-2
37
Dutasteride Approved, Investigational Phase 2,Phase 1 164656-23-9 152945 6918296
38
Dihydrotachysterol Approved Phase 2,Phase 1 67-96-9 5281010 5311071
39
Finasteride Approved Phase 2 98319-26-7 57363
40
tannic acid Approved Phase 1, Phase 2 1401-55-4
41
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
42
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
43
Enclomiphene Investigational Phase 2 15690-57-0
44 Zuclomiphene Phase 2
45 Estrogen Receptor Antagonists Phase 2
46 Clomiphene Phase 2
47 Estrogen Antagonists Phase 2
48 Chelating Agents Phase 2
49 Selective Estrogen Receptor Modulators Phase 2
50 Citrate Phase 2

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
2 Subcutaneous vs. Intramuscular Testosterone Completed NCT03091348 Phase 4 Testosterone
3 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
4 Testosterone Replacement in Diabetes With Vascular Disease (Version 2) Completed NCT00355537 Phase 4 Testosterone;0.9% saline
5 Vitamin D Treatment and Hypogonadism in Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
6 Testosterone for Men With Insulin Treated Type 2 Diabetes Completed NCT00349362 Phase 4 Testosterone;0.9% saline
7 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Recruiting NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
8 Periodontal Profile of Hypogonadic Men Recruiting NCT03176537 Phase 4 Testosterone gel;Placebos
9 Testosterone in Bariatric Patients Not yet recruiting NCT03721497 Phase 4 Testosterone Undecanoate
10 Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism Not yet recruiting NCT03851627 Phase 4 Testosterone Undecanoate;Placebo
11 Testosterone and Pain Sensitivity Withdrawn NCT01689896 Phase 4 Testosterone Gel;Placebo Gel
12 Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism Unknown status NCT01786473 Phase 3 Testogel 1%;Placebo
13 Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism Completed NCT01446042 Phase 3 Testosterone;Testosterone
14 Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men Completed NCT03868059 Phase 3 LPCN 1021
15 Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). Completed NCT03242590 Phase 3 LPCN 1021
16 Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) Completed NCT03242408 Phase 3 LPCN 1021
17 Safety and Efficacy Trial of Testosterone Undecanoate Completed NCT01765179 Phase 3 Oral testosterone undecanoate
18 Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men Completed NCT01403116 Phase 3 Oral testosterone undecanoate;topical testosterone gel
19 Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism Completed NCT02081300 Phase 3 Oral testosterone undecanoate, LPCN 1021;Topical testosterone gel 1.62 %
20 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Completed NCT01699178 Phase 3 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
21 Time to Eugonadal Range, Time to Steady State and Drying Time Completed NCT01228071 Phase 3 testosterone gel 2%
22 A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males Completed NCT02149264 Phase 3 Testosterone gel (FE 999303)
23 A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel Completed NCT01703741 Phase 3 Testosterone Gel (FE 999093)
24 A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel Completed NCT01665599 Phase 3 Testosterone gel (FE 999303)
25 Testosterone, Metformin, or Both, for Hypogonadism in Obese Males Completed NCT02514629 Phase 3 Placebo;Metformin;Testosterone Undecanoate;Metformin + Testosterone Undecanoate
26 The Comparison of Diagnostic TESE and TESA in Non-obstructive Azoospermic Completed NCT01210326 Phase 2, Phase 3
27 Open-Label Study of ARD-0403 in Testosterone Deficient Men Completed NCT00448955 Phase 3 ARD-0403
28 Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men Recruiting NCT03198728 Phase 3 SOV2012-F1;AndroGel
29 Open-Label Study of ARD-0403 in Testosterone Deficient Men Terminated NCT00562731 Phase 3 ARD-0403
30 Clomid in Men With Low Testosterone With and Without Prior Treatment Unknown status NCT01904734 Phase 2 Clomiphene
31 Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism Completed NCT02380755 Phase 2 Clomiphene Citrate;Placebo
32 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men Completed NCT00398580 Phase 2 Nanomilled testosterone;Nanomilled dutasteride;commercially available dutasteride
33 Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation Completed NCT00924612 Phase 2 Oral testosterone undecanoate (containing 300 mg of T)
34 Efficacy, Pharmacokinetics and Safety of Testosterone Completed NCT01370369 Phase 2 Testosterone gel (FE 99903)
35 Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism Completed NCT02777242 Phase 2
36 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride
37 Pharmacokinetic Study to Determine Time to Steady-state Completed NCT00911586 Phase 2 Testosterone undecanoate
38 Safety of Testosterone Undecanoate i.m. in Hypogonadal Men Completed NCT00452322 Phase 2 Testosterone Substitution by Testosterone Undecanoate i.m.
39 Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men Completed NCT02697188 Phase 2 Testosterone undecanoate;Testosterone enanthate
40 Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men Completed NCT00695110 Phase 2 Testosterone undecanoate (TU);TU + testosterone enanthate (TE);Testosterone undecanoate (TU);TU + testosterone enanthate (TE)
41 A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Terminated NCT03335254 Phase 1, Phase 2 TSX-011
42 Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride Completed NCT00400335 Phase 1 Nanomilled testosterone;commercially available dutasteride;Nanomilled dutasteride
43 Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism Recruiting NCT02966652 Phase 1 DITEST;Testosterone undecanoate
44 Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia Unknown status NCT02008799 Not Applicable
45 The Effect of Low Electrical Current on Testicular Spermatocyte Count Unknown status NCT02617173 Not Applicable
46 Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males Completed NCT03541395 Not Applicable GnRH antagonist
47 Registry of Hypogonadism in Men Completed NCT00858650
48 ESPRIT Study in Hypogonadal Men Completed NCT01143818 AndroGel (testosterone gel) 1%
49 Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice Completed NCT00410306 Testosterone Undecanoate (Nebido, BAY86-5037)
50 Older Men and Testosterone Completed NCT00119483 Not Applicable Nebido (Testosterone Undecanoate)

Search NIH Clinical Center for Hypogonadism, Male

Genetic Tests for Hypogonadism, Male

Genetic tests related to Hypogonadism, Male:

# Genetic test Affiliating Genes
1 Male Hypogonadism 30

Anatomical Context for Hypogonadism, Male

MalaCards organs/tissues related to Hypogonadism, Male:

42
Bone, Testes, Bone Marrow, Testis, Endothelial, Prostate, Liver

Publications for Hypogonadism, Male

Articles related to Hypogonadism, Male:

(show top 50) (show all 225)
# Title Authors Year
1
Use of medicinal doses of zinc as a safe and efficient coadjutant in the treatment of male hypogonadism. ( 30767598 )
2019
2
Downregulation of leptin receptor and kisspeptin/GPR54 in the murine hypothalamus contributes to male hypogonadism caused by high-fat diet-induced obesity. ( 29948931 )
2018
3
Metabolic Syndrome in Male Hypogonadism. ( 29895018 )
2018
4
Novel Therapy for Male Hypogonadism. ( 29886559 )
2018
5
Metabolic patterns in insulin-resistant male hypogonadism. ( 29867095 )
2018
6
Metabolic patterns in insulin-sensitive male hypogonadism. ( 29844353 )
2018
7
The safety of available treatments of male hypogonadism in organic and functional hypogonadism. ( 29334271 )
2018
8
Secondary male hypogonadism: A prevalent but overlooked comorbidity of obesity. ( 29974886 )
2018
9
Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism. ( 29145707 )
2018
10
Management of male hypogonadism and testosterone therapy: European Association of Urology position statement on the role of the urologist. ( 28988029 )
2018
11
Clinical and biochemical correlates of male hypogonadism in type 2 diabetes. ( 29145714 )
2018
12
Variation in Practice Pattern of Male Hypogonadism: A Comparative Analysis of Primary Care, Urology, Endocrinology, and HIV Specialists. ( 29183245 )
2018
13
Homozygous nonsense mutation Trp28X in the LHB gene causes male hypogonadism. ( 29476300 )
2018
14
Evaluation and Treatment of Male Hypogonadism. ( 29550857 )
2018
15
The complex association between metabolic syndrome and male hypogonadism. ( 29656047 )
2018
16
Possible mechanisms underlying fatty liver in a rat model of male hypogonadism: A protective role for testosterone. ( 29674209 )
2018
17
Clinical practice update on testosterone therapy for male hypogonadism: Contrasting perspectives to optimize care. ( 30358898 )
2018
18
Approaches to male hypogonadism in primary care. ( 28085783 )
2017
19
Serum testosterone levels in male hypogonadism: Why and when to check-A review. ( 28980739 )
2017
20
Re: Importance of Abdominal Circumference and Body Mass Index Values in Predicting Male Hypogonadism-A Practical Approach. ( 28208556 )
2017
21
EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM. ( 28225313 )
2017
22
European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone Therapy. ( 28249799 )
2017
23
Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health. ( 28408926 )
2017
24
Importance of abdominal circumference and body mass index values in predicting male hypogonadism - A practical approach. ( 27598980 )
2016
25
The Role of Estrogen Modulators in Male Hypogonadism and Infertility. ( 27601965 )
2016
26
Emerging medication for the treatment of male hypogonadism. ( 27552127 )
2016
27
Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. ( 27510348 )
2016
28
Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. ( 27581270 )
2016
29
Male Hypogonadism Causes Obesity Associated with Impairment of Hepatic Gluconeogenesis in Mice. ( 27040631 )
2016
30
Enclomiphene citrate for the treatment of secondary male hypogonadism. ( 27337642 )
2016
31
Evaluation and treatment of male hypogonadism in primary care. ( 27434384 )
2016
32
Re: Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis. ( 26853008 )
2016
33
Human Immunodeficiency Virus Infection and Male Hypogonadism: A Review. ( 26638598 )
2015
34
Erratum: correction to: the pharmacotherapy of male hypogonadism besides androgens. ( 25773647 )
2015
35
Treatment of hypogonadotropic male hypogonadism: Case-based scenarios. ( 25949938 )
2015
36
Late-onset Male Hypogonadism and Fertility Potential in Thalassemia Major Patients: Two Emerging Issues. ( 26185612 )
2015
37
Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis. ( 26205546 )
2015
38
Use of Hormone Testing for the Diagnosis and Evaluation of Male Hypogonadism and Monitoring of Testosterone Therapy: Application of Hormone Testing Guideline Recommendations in Clinical Practice. ( 26272690 )
2015
39
Editorial Comment on "Use of Hormone Testing for the Diagnosis and Evaluation of Male Hypogonadism and Monitoring of Testosterone Therapy: Application of Hormone Testing Guideline Recommendations in Clinical Practice". ( 26294039 )
2015
40
Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients. ( 26316882 )
2015
41
Evidence of male hypogonadism at an early age as a familial risk of type 2 diabetes. ( 26639184 )
2015
42
Male hypogonadism and metabolic syndrome. ( 25040289 )
2015
43
The pharmacotherapy of male hypogonadism besides androgens. ( 25523084 )
2015
44
Bone benefits of testosterone replacement therapy in male hypogonadism. ( 24994579 )
2014
45
Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. ( 25384570 )
2014
46
Controversies in the treatment of male hypogonadism. ( 24680460 )
2014
47
An update on male hypogonadism therapy. ( 24758365 )
2014
48
Selective estrogen receptor modulators, male hypogonadism, and infertility. ( 25044078 )
2014
49
Treatment options for male hypogonadism. ( 23627244 )
2013
50
Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. ( 23258624 )
2013

Variations for Hypogonadism, Male

Expression for Hypogonadism, Male

Search GEO for disease gene expression data for Hypogonadism, Male.

Pathways for Hypogonadism, Male

Pathways related to Hypogonadism, Male according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.08 LEP LHCGR

GO Terms for Hypogonadism, Male

Biological processes related to Hypogonadism, Male according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.16 BGLAP LEP
2 response to nutrient levels GO:0031667 8.96 BGLAP LEP
3 response to activity GO:0014823 8.62 BGLAP LEP

Sources for Hypogonadism, Male

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....